Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Open accessAbstract
The rapid advancement of nanomedicine and nanoparticle (NP) materials presents novel solutions potentially capable of revolutionizing health care by improving efficacy, bioavailability, drug targeting, and safety. NPs are intriguing when considering medical applications because of their essential and unique qualities, including a significantly higher surface to mass ratio, quantum properties, and the potential to adsorb and transport drugs and other compounds. However, NPs must overcome or navigate several biological barriers of the human body to successfully deliver drugs at precise locations. Engineering the drug carrier biointerface can help overcome the main biological barriers and optimize the drug delivery in a more personalized manner. This review discusses the significant heterogeneous biological delivery barriers and how biointerface engineering can promote drug carriers to prevail over hurdles and navigate in a more personalized manner, thus ushering in the era of Precision Medicine. We also summarize the nanomedicines' current advantages and disadvantages in drug administration, from natural/synthetic sources to clinical applications. Additionally, we explore the innovative NP designs used in both non-personalized and customized applications as well as how they can attain a precise therapeutic strategy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Modularity of nanoparticle design combined with physicochemical properties enables radiopharmaceuticals to cross biological barriers that traditionally hindered drug delivery.
“The modularity of nanoparticle design, combined with their inherent physicochemical properties, enables radiopharmaceuticals to cross biological barriers that traditionally hindered drug delivery [82].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [82]
The 'Alternative strategies to enhance nanoparticle design' section says adaptable nanoparticle design can be tailored to overcome biological barriers, and the Conclusions identify size, shape, charge, and surface properties as design variables. The cited paper supports this general point about nanotherapeutic delivery, but the passages do not establish it specifically for radiopharmaceuticals. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 223 · Cited by 259
- Authors
- Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J.
- Affiliations
- Shenzhen University (CN)
- University of Verona (IT)
- Corresponding author
- Wu, Jun
- Venue
- Journal of Nanobiotechnology
- Published
- 2022-08-31
- Volume
- 20
- Issue
- 1
- Pages
- 395-395
- ISSN
- 1477-3155 (ISSN-L)
- PMC
- PMC9428887
- OpenAlex
- W4293747581
- Cited by
- 259
- References
- 223
- Citations by year
- 2026: 72 · 2025: 89 · 2024: 63 · 2023: 31 · 2022: 4
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Nanobiotechnology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Guangdong Basic and Applied Basic Research Foundation ((2020A1515010613, 2021A1515220176))
- Guangdong Medical Science and Technology Research Foundation ((A2021077))
- Retired Expert Program of Guangdong Province ((202020031911500002))
- Sanming Project of Medicine in Shenzhen ((No.SZSM202111020))
- The Key Basic Research Project of Shenzhen Science and Technology Program ((JCYJ20200109115635440))
- Shenzhen-Hong Kong-Macau Technology Research Programme ((Type C: SGDX2020110309300301))
- National Natural Science Foundation of China ((82172214))
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
- Keywords
- nanoparticle drug carriers, precision drug delivery, biological barriers, nanomedicine, targeted drug delivery, personalized medicine, nanoparticle design, drug delivery systems
- MeSH terms
- Drug Carriers, Humans, Drug Delivery Systems, Nanomedicine, Nanoparticles, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
